TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00178256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
Study: NCT02900781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steprite™
Description: Steprite™ Device shoe insert monitoring device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: No Device. Standard of care physical therapy
Study: NCT02472314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.3% Liposomal Bupivacaine
Description: local tissue infiltration of Liposomal Bupivacaine during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.3% Liposomal Bupivacaine
Description: local tissue infiltration of Liposomal Bupivacaine during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine
Description: Continues nerve block with Bupivacaine during surgery and postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine
Description: Continues nerve block with Bupivacaine during surgery and postoperatively
Study: NCT03667716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701
Description: COM701 monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701
Description: COM701 monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 with Opdivo (Nivolumab).
Description: COM701 in combination with Opdivo (Nivolumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM701 with Opdivo (Nivolumab).
Description: COM701 in combination with Opdivo (Nivolumab).
Study: NCT00440674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel-eluting coronary stent system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel-eluting coronary stent system
Study: NCT00524238

Intervention type: DRUG
Group type: OTHER
Intervention: L-thyroxine
Description: The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
Study: NCT01510613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide and Dexamethasone
Description: Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
Study: NCT03507829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin isophane, Humulin N (Eli Lilly)
Description: Human insulin isophane, Humulin N (Eli Lilly)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Description: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Study: NCT03089372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARIES-ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ARIES-ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
Study: NCT03443596

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Early intensive BP control
Description: Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
Study: NCT01477749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Study: NCT04027335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leva
Description: Vaginal device used for pelvic floor muscle exercises
Study: NCT03076658

Intervention type: RADIATION
Group type: OTHER
Intervention: EOS imaging
Description: The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
Study: NCT03560141

Intervention type: DEVICE
Group type: OTHER
Intervention: LID011121 contact lens
Description: Investigational silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: LID011121 contact lens
Description: Investigational silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study: NCT03670147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PF-SCS programming
Description: In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PF-SCS programming
Description: In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
Study: NCT03897166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trimodality
Description: Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
Study: NCT03164733

Intervention type: OTHER
Intervention: incubation
Description: standardized wear particles are co-incubated with isolated patient cells (monocytes)

Intervention type: OTHER
Intervention: incubation
Description: standardized wear particles are co-incubated with isolated patient cells (monocytes)

Intervention type: OTHER
Intervention: incubation
Description: standardized wear particles are co-incubated with isolated patient cells (monocytes)

Intervention type: OTHER
Intervention: incubation
Description: standardized wear particles are co-incubated with isolated patient cells (monocytes)
Study: NCT00479037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full Length Parathyroid Hormone, PTH(1-84)
Description: Once daily subcutaneous injection in the abdomen by self administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium Ranelate
Description: The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
Study: NCT03406234

Intervention type: OTHER
Intervention: No intervention.
Description: Cross-sectional observation without interventions.
Study: NCT03562169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Description: 4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
Description: 4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional autologous stem cell transplant (ASCT-con)
Description: Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmented autologous stem cell transplant (ASCT-aug)
Description: Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITD consolidation and ixazomib maintenance vs. No further therapy
Description: Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ITD consolidation and ixazomib maintenance vs. No further therapy
Description: Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.
Study: NCT00884286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplidin®
Description: Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Study: NCT01406561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS103HP-S
Description: Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
Study: NCT01779921

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.

Intervention type: DRUG
Intervention: Fresh frozen plasma (Source unspecified)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.

Intervention type: DRUG
Intervention: Plasma-derived FVII (LFB)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.

Intervention type: DRUG
Intervention: Prothrombin Complex conc. (PCC)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.

Intervention type: DRUG
Intervention: Plasma-derived FVII conc. (pdFVII Baxter)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.

Intervention type: DRUG
Intervention: Plasma-derived FVII conc. (pdFVII PFL)
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Study: NCT01010893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P and Fluval AB influenza vaccines
Description: Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval P monovalent influenza vaccine
Description: Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
Study: NCT03531463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment with Reversed Total Shoulder Prosthesis
Description: The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used
Study: NCT01336335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP
Study: NCT01203241

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein encircling
Description: Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein encircling plus roof ablation
Description: Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
Study: NCT01817543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoloGel
Description: Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
Study: NCT01785641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftazidime+ciprofloxacin
Description: 2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftazidime monotherapy
Description: ceftazidime IP for gram negative bacterial peritonitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefazolin+gentamicin
Description: cefazolin IP + gentamicin IP for gram positive bacterial peritonitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin monotherapy
Description: cefazolin IP for gram positive bacterial peritonitis
Study: NCT00636584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside
Description: sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03100695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated autologous PRP-BMA
Description: Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
Study: NCT03189225

Intervention type: OTHER
Group type: OTHER
Intervention: Capillary And Venous Accuracy
Description: Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
Study: NCT03267329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duowell®
Description: telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: telmisartan 80mg
Study: NCT03839563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
Study: NCT02912195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Description: Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Emergency department provider chooses appropriate dose of intravenous morphine
Study: NCT02095600

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgical thalamotomy
Study: NCT01515956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
Study: NCT00178620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Description: Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase 10 U
Description: Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urgent Percutaneous Coronary Intervention (PCI)
Study: NCT01260181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg tablet will be given orally daily.
Study: NCT01312792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amoxycilline, Cephradine followed by follow up on day 3
Description: Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injectable ampicillin followed by urgent referral
Description: Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
Study: NCT04879446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor(CGF)
Description: Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet rich fibrin (A-PRF)
Description: Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of concentrated growth factor study group
Description: Traditional implant methods applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control side of advanced platelet rich fibrin study group
Description: Traditional implant methods applied.
Study: NCT02617121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral gabapentin 300 mg 1 hour before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: ramosetron 0.3 mg iv at end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin and Ramosetron
Description: oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
Study: NCT01175239

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Description: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Study: NCT00839098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction Group: Power seat function usage instruction- verbal and written instruction
Description: Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
Study: NCT00178620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Study: NCT02933463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embrace Wetbond
Description: not require an additional bonding agent hydrophilic, fluoride releasing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinpro sealant
Study: NCT02832765

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: A
Description: Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: B
Description: Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C
Description: Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: D
Description: Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases